세계의 차세대 시퀀싱 시장 - 규모, 점유율, 동향 분석 보고서 : 기술별, 제품별, 용도별, 워크플로우별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Targeted Sequencing & Resequencing, WGS), By Product (Platform, Consumables), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,833,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,318,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,288,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

차세대 시퀀싱 시장 요약

세계의 차세대 시퀀싱 시장 규모는 2024년 95억 6,000만 달러로 추정되었으며, 2033년까지 422억 5,000만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 CAGR 18.0%로 성장할 전망입니다. 이러한 성장은 고급 유전체 조사에 대한 수요 증가, 임상 진단에서 차세대 시퀀싱(NGS)의 응용 확대 및 시퀀싱 플랫폼에서의 지속적인 기술 진보에 의해 견인되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장의 변수, 동향, 범위

• 시장 세분화 및 범위
• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조시장 전망
• 시장 동향과 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 시장 분석 도구
  • SWOT 분석; 요인별(정치 및 법률, 경제 및 기술)
  • Porter's Five Forces 분석

제4장 기술별 비즈니스 분석

• 부문 대시보드
• 차세대 시퀀싱 데이터 분석 시장 : 기술 변동 분석
• 타겟 시퀀싱 및 리시퀀싱
  • DNA 기반 타겟 시퀀싱 및 리시퀀싱
  • RNA 기반 타겟 시퀀싱 및 리시퀀싱
• 전체 유전체 시퀀싱
• 전체 엑솜 시퀀싱

제5장 제품별 비즈니스 분석

• 부문 대시보드
• 차세대 시퀀싱 데이터 분석 시장 : 제품 변동 분석
• 플랫폼
  • 시퀀싱
  • 데이터 분석
• 소모품
  • 샘플 준비
  • 타겟 엔리치먼트
  • 기타

제6장 용도별 비즈니스 분석

• 부문 대시보드
• 차세대 시퀀싱 데이터 분석 시장 : 용도 변동 분석
• 종양
  • 진단 및 스크리닝
  • 임상조사
• 임상조사
  • 감염증
  • 특발성 질환
  • 유전성 질환
  • 비감염성 질환 및 기타 질환
• 생식보건
  • NIPT
  • PGT
  • 신생아 유전자 스크리닝
  • 단일 유전자 분석 시장
• HLA 타이핑 및 면역시스템 모니터링
• 군유전체학, 역학, 의약품 개발
• 농업유전체학 및 법의학
• 소비자 유전체학

제7장 워크플로우별 비즈니스 분석

• 부문 대시보드
• 차세대 시퀀싱 데이터 분석 시장 : 워크플로우 변동 분석
• 사전 시퀀싱
  • 핵산 추출
  • 라이브러리 준비
• 시퀀싱
• 데이터 분석
  • 1차 데이터 분석 시장 추계 및 예측, 2021-2033년
  • 2차 데이터 분석 시장 추계 및 예측, 2021-2033년
  • 3차 데이터 분석 시장 추계 및 예측, 2021-2033년

제8장 최종 용도별 비즈니스 분석

• 부문 대시보드
• 차세대 시퀀싱 시장 : 최종 사용자 변동 분석
• 학술연구
• 임상조사
• 병원 및 클리닉
• 제약 및 생명 공학 기업
• 기타

제9장 지역별 비즈니스 분석

• 차세대 시퀀싱 시장 점유율(지역별, 2024년 및 2033년)
• 북미
  • 북미의 차세대 시퀀싱 시장, 2021-2033년
  • 미국
  • 캐나다
  • 멕시코
  • 유럽
  • 유럽의 차세대 시퀀싱 시장, 2021-2033년
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 차세대 시퀀싱 시장, 2021-2033년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 라틴아메리카의 차세대 시퀀싱 시장, 2021-2033년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • MEA의 차세대 시퀀싱 시장, 2021-2033년
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 기업/경쟁의 분류
• 전략 매핑
• 기업시장 포지셔닝 분석, 2024년
• 기업 프로파일
  • Illumina
  • F. Hoffman-La Roche Ltd.
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Oxford Nanopore Technologies
  • Revvity, Inc.
  • PacBio
  • Merk KGaA
  • BGI

JHS

영문 목차

영문목차

Next Generation Sequencing Market Summary

The global next-generation sequencing market size was estimated at USD 9.56 billion in 2024 and is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. This growth is driven by the increasing demand for advanced genomic research, rising applications of next-generation sequencing (NGS) in clinical diagnostics, and ongoing technological advancements in sequencing platforms.

Global Next-Generation Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the next-generation sequencing market based on technology, product, workflow, end-use, and region.

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• WGS
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
  • DNA-based
  • RNA-based
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Platform
  • Sequencing
  • Data Analysis
• Consumables
  • Sample Preparation
  • Target Enrichment
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
  • Diagnostics and Screening
  • Oncology Screening
  • Sporadic Cancer
  • Inherited Cancer
  • Companion Diagnostics
  • Other Diagnostics
  • Research Studies
• Clinical Investigation
  • Infectious Diseases
  • Inherited Diseases
  • Idiopathic Diseases
  • Non-Communicable/Other Diseases
• Reproductive Health
  • NIPT
  • Aneuploidy
  • Microdeletions
  • PGT
  • Newborn Genetic Screening
  • Single Gene Analysis
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Sequencing
  • Nucleic Acid Extraction
  • Library Preparation
• Sequencing
  • NGS Data Analysis
  • NGS Primary Data Analysis
  • NGS Secondary Data Analysis
  • NGS Tertiary Data Analysis
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other Users
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Technology Segment
  • 1.1.2. Product Segment
  • 1.1.3. Workflow Segment
  • 1.1.4. Application Segment
  • 1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Market Drivers Analysis
    • 3.4.1.1. Decreasing costs for genetic sequencing
    • 3.4.1.2. Development of companion diagnostics and personalized medicine
    • 3.4.1.3. Rising clinical opportunity for NGS technology
    • 3.4.1.4. Technological advancements in cloud computing
  • 3.4.2. Market Restraint Analysis
    • 3.4.2.1. Lack of computational efficiency for data management
    • 3.4.2.2. Non-value-based NGS reimbursement policy and regulation status
    • 3.4.2.3. Challenges associated with NGS implementation
• 3.5. Market Analysis Tools
  • 3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Technology Business Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Sequencing Data Analysis Market: Technology Movement Analysis
• 4.3. Targeted Sequencing & Resequencing
  • 4.3.1. Targeted Sequencing & Resequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 4.3.2. DNA-Based Targeted Sequencing & Resequencing
    • 4.3.2.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3.3. RNA-Based Targeted Sequencing & Resequencing
    • 4.3.3.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
• 4.4. Whole Genome Sequencing
  • 4.4.1. Whole Genome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 4.5. Whole Exome Sequencing
  • 4.5.1. Whole Exome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Segment Dashboard
• 5.2. Next Generation Sequencing Data Analysis Market: Product Movement Analysis
• 5.3. Platforms
  • 5.3.1. Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.3.2. Sequencing
    • 5.3.2.1. Sequencing Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.3.3. Data Analysis
    • 5.3.3.1. Data Analysis Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Consumables Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.2. Sample Preparation
    • 5.4.2.1. Sample Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.3. Target Enrichment
    • 5.4.3.1. Target Enrichment Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Next Generation Sequencing Data Analysis Market: Application Movement Analysis
• 6.3. Oncology
  • 6.3.1. Oncology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.3.2. Diagnostics & Screening
    • 6.3.2.1. Diagnostics & Screening Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.2. Oncology screening
      • 6.3.2.2.1. Oncology Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
      • 6.3.2.2.2. Sporadic Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
      • 6.3.2.2.3. Inherited Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.3. Companion diagnostics
      • 6.3.2.3.1. Companion Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.4. Other Diagnostics
      • 6.3.2.4.1. Other Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.3.3. Research Studies
    • 6.3.3.1. Research Studies Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.4. Clinical Investigation
  • 6.4.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.2. Infectious Diseases
    • 6.4.2.1. Infectious Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.3. Idiopathic Diseases
    • 6.4.3.1. Idiopathic Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.4. Inherited Diseases
    • 6.4.4.1. Inherited Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.5. Non-communicable/other Diseases
    • 6.4.5.1. Reproductive Health Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.5. Reproductive Health
  • 6.5.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.2. NIPT
    • 6.5.2.1. NIPT Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.5.2.2. Aneuploidy
      • 6.5.2.2.1. Aneuploidy Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.5.2.3. Microdeletions
      • 6.5.2.3.1. Microdeletions Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.3. PGT
    • 6.5.3.1. PGT Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.4. Newborn Genetic Screening
    • 6.5.4.1. Newborn Genetic Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.5. Single Gene Analysis Market
    • 6.5.5.1. Single Gene Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.6. HLA Typing/Immune System Monitoring
  • 6.6.1. HLA Typing/Immune System Monitoring Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.7. Metagenomics, Epidemiology & Drug Development
  • 6.7.1. Metagenomics, Epidemiology & Drug Development Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.8. Agrigenomics & Forensics
  • 6.8.1. Agrigenomics & Forensics Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.9. Consumer Genomics
  • 6.9.1. Consumer Genomics Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 7. Workflow Business Analysis

• 7.1. Segment Dashboard
• 7.2. Next Generation Sequencing Data Analysis Market: Workflow Movement Analysis
• 7.3. Presequencing
  • 7.3.1. Presequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.3.2. Nucleic Acid Extraction
    • 7.3.2.1. Nucleic Acid Extraction Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.3.3. Library Preparation
    • 7.3.3.1. Library Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.4. Sequencing
  • 7.4.1. Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.5. Data Analysis
  • 7.5.1. Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.2. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.2.1. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.3. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.3.1. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.4. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.4.1. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. Next Generation Sequencing Market: End - Use Movement Analysis
• 8.3. Academic Research
  • 8.3.1. Academic Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.4. Clinical Research
  • 8.4.1. Clinical Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.5. Hospitals & Clinics
  • 8.5.1. Hospitals & Clinics Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.6. Pharmaceutical & Biotech Entities
  • 8.6.1. Pharmaceutical & Biotech Entities Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.7. Other Users
  • 8.7.1. Other Users Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Next Generation Sequencing Market Share By Region, 2024 & 2033
• 9.2. North America
  • 9.2.1. North America next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. U.S. next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.2.3. Target disease prevalence
    • 9.2.2.4. Competitive scenario
    • 9.2.2.5. Regulatory framework
    • 9.2.2.6. Reimbursement scenario
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Canada next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.3.3. Target disease prevalence
    • 9.2.3.4. Competitive scenario
    • 9.2.3.5. Regulatory framework
    • 9.2.3.6. Reimbursement scenario
  • 9.2.4. Mexico
    • 9.2.4.1. Key country dynamics
    • 9.2.4.2. Mexico next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.4.3. Target disease prevalence
    • 9.2.4.4. Competitive scenario
    • 9.2.4.5. Regulatory framework
    • 9.2.4.6. Reimbursement scenario
  • 9.2.5. Europe
  • 9.2.6. Europe Next Generation Sequencing market, 2021 - 2033 (USD Million)
  • 9.2.7. Germany
    • 9.2.7.1. Key country dynamics
    • 9.2.7.2. Germany next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.7.3. Target disease prevalence
    • 9.2.7.4. Competitive scenario
    • 9.2.7.5. Regulatory framework
    • 9.2.7.6. Reimbursement scenario
  • 9.2.8. UK
    • 9.2.8.1. Key country dynamics
    • 9.2.8.2. UK next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.8.3. Target disease prevalence
    • 9.2.8.4. Competitive scenario
    • 9.2.8.5. Regulatory framework
    • 9.2.8.6. Reimbursement scenario
  • 9.2.9. France
    • 9.2.9.1. Key country dynamics
    • 9.2.9.2. France next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.9.3. Target disease prevalence
    • 9.2.9.4. Competitive scenario
    • 9.2.9.5. Regulatory framework
    • 9.2.9.6. Reimbursement scenario
  • 9.2.10. Italy
    • 9.2.10.1. Key country dynamics
    • 9.2.10.2. Italy next generation sequencing (NGS) market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.10.3. Target disease prevalence
    • 9.2.10.4. Competitive scenario
    • 9.2.10.5. Regulatory framework
    • 9.2.10.6. Reimbursement scenario
  • 9.2.11. Spain
    • 9.2.11.1. Key country dynamics
    • 9.2.11.2. Spain next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.11.3. Target disease prevalence
    • 9.2.11.4. Competitive scenario
    • 9.2.11.5. Regulatory framework
    • 9.2.11.6. Reimbursement scenario
  • 9.2.12. Denmark
    • 9.2.12.1. Key country dynamics
    • 9.2.12.2. Denmark next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.12.3. Target disease prevalence
    • 9.2.12.4. Competitive scenario
    • 9.2.12.5. Regulatory framework
    • 9.2.12.6. Reimbursement scenario
  • 9.2.13. Sweden
    • 9.2.13.1. Key country dynamics
    • 9.2.13.2. Sweden next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.13.3. Target disease prevalence
    • 9.2.13.4. Competitive scenario
    • 9.2.13.5. Regulatory framework
    • 9.2.13.6. Reimbursement scenario
  • 9.2.14. Norway
    • 9.2.14.1. Key country dynamics
    • 9.2.14.2. Norway next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.14.3. Target disease prevalence
    • 9.2.14.4. Competitive scenario
    • 9.2.14.5. Regulatory framework
    • 9.2.14.6. Reimbursement scenario
• 9.3. Asia Pacific
  • 9.3.1. Asia Pacific next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.3.2. Japan
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Japan next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.2.3. Target disease prevalence
    • 9.3.2.4. Competitive scenario
    • 9.3.2.5. Regulatory framework
    • 9.3.2.6. Reimbursement scenario
  • 9.3.3. China
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. China next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.3.3. Target disease prevalence
    • 9.3.3.4. Competitive scenario
    • 9.3.3.5. Regulatory framework
    • 9.3.3.6. Reimbursement scenario
  • 9.3.4. India
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. India next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.4.3. Target disease prevalence
    • 9.3.4.4. Competitive scenario
    • 9.3.4.5. Regulatory framework
    • 9.3.4.6. Reimbursement scenario
  • 9.3.5. South Korea
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. South Korea next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.5.3. Target disease prevalence
    • 9.3.5.4. Competitive scenario
    • 9.3.5.5. Regulatory framework
    • 9.3.5.6. Reimbursement scenario
  • 9.3.6. Australia
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Australia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.6.3. Target disease prevalence
    • 9.3.6.4. Competitive scenario
    • 9.3.6.5. Regulatory framework
    • 9.3.6.6. Reimbursement scenario
  • 9.3.7. Thailand
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Thailand next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.7.3. Target disease prevalence
    • 9.3.7.4. Competitive scenario
    • 9.3.7.5. Regulatory framework
    • 9.3.7.6. Reimbursement scenario
• 9.4. Latin America
  • 9.4.1. Latin America next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.4.2. Brazil
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Brazil next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Regulatory framework
    • 9.4.2.6. Reimbursement scenario
  • 9.4.3. Argentina
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Argentina next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. Regulatory framework
    • 9.4.3.6. Reimbursement scenario
• 9.5. MEA
  • 9.5.1. MEA next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.5.2. South Africa
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. South Africa next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Regulatory framework
    • 9.5.2.6. Reimbursement scenario
  • 9.5.3. Saudi Arabia
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Saudi Arabia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. Regulatory framework
    • 9.5.3.6. Reimbursement scenario
  • 9.5.4. UAE
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. UAE next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Regulatory framework
    • 9.5.4.6. Reimbursement scenario
  • 9.5.5. Kuwait
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Kuwait next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.5.3. Target disease prevalence
    • 9.5.5.4. Competitive scenario
    • 9.5.5.5. Regulatory framework
    • 9.5.5.6. Reimbursement scenario

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Illumina
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. F. Hoffman-La Roche Ltd.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. QIAGEN
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Thermo Fisher Scientific, Inc.
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Bio-Rad Laboratories, Inc.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Oxford Nanopore Technologies
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Revvity, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. PacBio
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Merk KGaA
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. BGI
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives

관련자료